Drugs / Ethosuximide
Ethosuximide
also known as
CI-366 · CN-10,395 · Emeside · ESX · Ethosuximidum · Etosuximida · ETX · NSC-64013 · +4 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ZARONTIN | — | 1960-11-02 | fda.gov ↗ |
Trials 8
195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030203120322033
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03887624 | May 2019 → Apr 2021 | major depressive disorder | Zhejiang University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01122381 | Dec 2011 → Apr 2014 | migraine disorder | US Department of Veterans Affairs | Terminated | No outcome recorded Stop: Enrollment |
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT04431778 | Nov 2020 → Nov 2023 | neuropathy, painful | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 2 | NCT02973542 | Feb 2018 → Mar 2023 | irritable bowel syndrome | University Hospital, Clermont-Ferrand | Completed | Missed primary |
| Phase 2 | NCT02100046 | Mar 2014 → Sep 2016 | neuropathy, painful, traumatic neuropathy | University Hospital, Clermont-Ferrand | Completed | Missed primary |
| Phase 2 | NCT01278004 | May 2010 → Jul 2014 | cancer, peripheral neuropathy | Royal Marsden NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT00689585 | Sep 2008 → Jul 2010 | complex regional pain syndrome | McGill University Health Centre/Research Institute of the McGill University Health Centre | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04217733 | Nov 2019 → Dec 2030 expected | irritable bowel syndrome | Tanta University | Recruiting | Met primary |
| Comparator or background therapy4 trials | ||||||
| Phase 3 | NCT04274179 Comparator | Aug 2020 → May 2028 expected | childhood absence epilepsy | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 3 | NCT00088452 Comparator | Jul 2004 → Jan 2013 | childhood absence epilepsy | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT02205931 Comparator | Jan 2015 → Jun 2018 | epilepsy | University College, London | Unknown | No outcome recorded |
| Phase 4 | NCT00552526 Comparator | Nov 2007 → Jan 2011 | epilepsy | Oslo University Hospital | Unknown | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ethosuximide | “Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate,...” NCT00552526 ↗ |
| Known as | CI-366 | ChEMBL registry synonym — accepted as the source's own label CHEMBL696 ↗ |
| Known as | CN-10,395 | ChEMBL registry synonym — accepted as the source's own label CHEMBL696 ↗ |
| Known as | Emeside | ChEMBL registry synonym — accepted as the source's own label CHEMBL696 ↗ |
| Known as | ESX | “ethosuximide (ESX)” NCT01122381 ↗ |
| Known as | Ethosuximidum | ChEMBL registry synonym — accepted as the source's own label CHEMBL696 ↗ |
| Known as | Etosuximida | ChEMBL registry synonym — accepted as the source's own label CHEMBL696 ↗ |
| Known as | ETX | “Ethosuximide (ETX), an anticonvulsant and a T-type channel blocker has shown analgesic effect in several chronic pain models but has not yet been evaluated in patients with...” PMID 29577519 ↗ Apr 2018 |
| Known as | NSC-64013 | ChEMBL registry synonym — accepted as the source's own label CHEMBL696 ↗ |
| Known as | PM-671 | ChEMBL registry synonym — accepted as the source's own label CHEMBL696 ↗ |
| Known as | Pyknolepsinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL696 ↗ |
| Known as | Suxinutin | ChEMBL registry synonym — accepted as the source's own label CHEMBL696 ↗ |
| Known as | Zarontin | ChEMBL registry synonym — accepted as the source's own label CHEMBL696 ↗ |
| Action | Restore | “low serotonin levels can be rescued by treatment with the childhood antiepileptic drug ethosuximide (ESX)” NCT01122381 ↗ |
| Modality | Small molecule | — CHEMBL696 ↗ |
| Route | Oral | “receive orally, either ethosuximide or placebo” NCT00689585 ↗ |